Physician profile
Douglas E Mattingly
NPI 1801851886
$5,547.02
in general payments reported to CMS, 2019-2025
20 companies · $433 in 2025
The $433 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,201 · 2020: $725 · 2021: $668 · 2022: $518 · 2023: $549 · 2024: $453 · 2025: $433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,435.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,435.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,810.73 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $1,362.23 | 2019-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $614.75 | 2019-2025 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $307.72 | 2019-2022 | |
| Lilly USA, LLC | $263.32 | 2019-2023 | Trulicity, Mounjaro |
| Comsort, INC | $150.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $146.05 | 2019 | |
| Supernus Pharmaceuticals, INC. | $142.10 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $132.54 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $124.93 | 2019 | |
| Glaxosmithkline, LLC. | $115.24 | 2019-2025 | Trelegy Ellipta |
| Amarin Pharma, INC. | $99.89 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.80 | 2019 | |
| Astellas Pharma US INC | $47.95 | 2019 | |
| Allergan, INC. | $35.73 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $35.51 | 2019 | |
| Alkermes, INC. | $29.73 | 2025 | Vivitrol |
| Novartis Pharmaceuticals Corporation | $27.46 | 2019-2022 | |
| Abbvie INC. | $23.60 | 2019 | |
| Pfizer INC. | $22.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Mattingly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.